Google
Trusted Resources: People & Places
Healthcare providers, researchers, and advocates
David Beidler, PhD
Researcher Senior Director, Precision Medicine, Early Clinical Development
Pfizer Inc.
Global Research and Development -
Rare Diseases Research Unit
1 Portland Street
Cambridge, Massachusetts, United States
As the Translational Sciences lead for the phosphodiesterase type 9 inhibitor project, Dr. Beidler contributed to the development, implementation, and analysis of pharmacodynamic biomarkers in the recent phase 1b study in stable sickle cell disease subjects. Dr. Beidler has over 17 years of pharmaceutical industry experience with biomarker/translational pharmacology strategy and clinical operations that span preclinical animal models, natural history/methodology studies, and early (Phase 1/2) clinical trials. Dr. Beidler has also served as the research project team leader and in vivo pharmacology lead on several pain/inflammation project teams that delivered multiple candidate compounds to the clinic.
Representative Publications:
Safety and Tolerability of PF-04447943 across a Clinical Trial Program Including 277 Patients
+myBinderRelated Content
-
Pediatric prescriber pratices of hyrdoxyurea in sickle cell diseaseHydroxyurea (HU) has been shown to be ef...
-
American Sickle Cell Anemia AssociationThe American Sickle Cell Anemia Associat...
-
Biree Andemariam, MDDr. Biree Andemariam is a hematologist a...
-
A novel approach to reducing admissions for children with sickle cell disease in pain crisis through individualizati...BACKGROUND:Vaso-occlusive crisis (VOC) i...
-
PCORI Board Approves $18 Million for Research on Sickle Cell DiseaseThe Patient-Centered Outcomes Research I...
-
Mandy DavidMandy David is a senior health communica...
-
Today’s Faces of Sickle Cell Disease: Swee Lay Thein, MB, BS, FRCP, FRCPath, DScSwee Lay Thein was educated in both Mala...
